{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066410","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.507986+00:00","generated_at":"2026-05-22T05:42:37.203509+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NewAmsterdam Pharma reports Q1 net loss $39.5M; cash $808.5M; EMA submission on track for 2H25","bullets":["Cash $808.5M at Mar 31, 2025, down from $834.2M at Dec 31, 2024.","Net loss $39.5M vs $93.8M YoY; revenue $3.0M vs $1.4M.","EMA submission expected 2H25 by partner Menarini; PREVAIL CVOT enrollment completed.","Adele Gulfo appointed to Board of Directors in April 2025.","R&D expenses $44.8M; SG&A $27.2M, up due to commercial launch prep."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066410","json":"https://secwatch.observer/filing/0000950170-25-066410.json","markdown":"https://secwatch.observer/filing/0000950170-25-066410.md","text":"https://secwatch.observer/filing/0000950170-25-066410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025066410/0000950170-25-066410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025066410/nams-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:42:37.203509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}